Company Information
ScPharmaceuticals was founded on January 2014. The company is based in Lexington, MA, USA . The number of employees in scPharmaceuticals is less than 50. Scpharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.Here is how scPharmaceuticals describes itself: "Our proprietary subcutaneous furosemide for HF diuresis is delivered via an on-body infusor for the outpatient treatment of congestion in patients with HF."
Funding & investors
scPharmaceuticals has received 3 rounds of venture funding. The total funding amount is around $126.6M.- GV (Corporate venture capital)
- OrbiMed (Private equity firm)
- Sun Pharma
- 5AM Ventures (Venture capital)
- Lundbeckfonden Ventures (Venture capital)
- Contact us if you are interested to see all 7 investors
Similar Companies [beta]
- Spero therapeutics
- Dalcor pharmaceuticals
- Gritstone oncology
- Citizen health
- Genomenon
- Correlia biosystems
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
News
scPharmaceuticals - Blog
- Site goes live
- scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)
- Poster on Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure
- John Tucker Appointed as Chief Executive Officer of scPharmaceuticals
- scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product
- scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing
Website goes live in November! Location: scpharmaceuticals.com Time: November 1, 2017 For more information, please contact us.The post Site goes live appeared first on scPharma.
FOR IMMEDIATE RELEASE: BURLINGTON, MA., — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA).The post <span class="normalcase">scPharmaceuticals</span> Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide) appeared first on scPharma.
Rene L. Myers,1 PhD, James Udelson2, MD, Barbara Cornelius1, Christopher G. Lohan1, Javier Zugasti1, PhD, Pieter Muntendam1, MD 1scPharmaceuticals, Inc.; 2Tufts Medical Center Poster Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure The post Poster on Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure appeared first on scPharma.
LEXINGTON, MA, April 26, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, announced the appointment of John Tucker as president and chief executive officer, effective immediately. Mr. Tucker was also elected to the board of directors of scPharmaceuticals.The post John Tucker Appointed as Chief Executive Officer of <span class="normalcase">scPharmaceuticals</span> appeared first on scPharma.
LEXINGTON, Mass., January 24, 2017 /PRNewswire/ – scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN). HFN is a clinical research initiative funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The primary goal of the HFN is to conduct multiple clinical trials to evaluate treatments and strategies to improve management of acute and chronic heart failure.The post <span class="normalcase"><span class="normalcase">scPharmaceuticals</span></span> Announces Start of <span class="normalcase">SUBQ-HF</span> <span class="normalcase">NHLBI</span> Study with Its Subcutaneous Furosemide Product appeared first on scPharma.
Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.The post <span class="normalcase">scPharmaceuticals</span> Announces Closing of $45.6 Million in Series <span class="normalcase">B</span> Financing appeared first on scPharma.
Share:
